CRISPR Gene Editing in Infectious Diseases: Market Overview, Pipeline Products, Clinical Trials, Challenges, Deals, Companies and Future Outlook
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
The report provides an overview of the potential of CRISPR-based therapeutics in the infectious disease space.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a precision gene-editing tool that enables targeted modification of DNA. It uses a guide RNA to direct a Cas enzyme (such as Cas9 or Cas12) to a specific genetic sequence, where it creates a cut and allows for the insertion, deletion, or correction of DNA. In infectious diseases, CRISPR may be used to directly disrupt viral genomes, edit host susceptibility genes, or engineer immune cells to fight persistent pathogens.
Scope
Overview of CRISPR gene editing, including history of development
Assessment of unmet needs and challenges in the space (gap anlysis)
Profiles of key pipeline products and emerging companies
Overview of major deals and acquisitions in the space between 2013 and 2025
Insights into ethical considerations and future outlook
Key Highlights
Report deliverables in the form of a PowerPoint report
Global scope of pipeline products
Reasons to Buy
Develop an understanding of the potential of CRISPR-based therapeutics in the infectious disease space.
Gain insights into the innovative products and technologies, and emerging companies with potential to shape the future market.
Recognize gaps, challenges, and areas of unmet need within this space.
Identify opportunities for consolidations, investments, and strategic partnerships.
Locus Biosciences
Intellia Therapeutics
Shanghai BDgene Therapeutics Co
SNIPR Biome
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports